BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Displays CDMO Expertise at Prestigious Biomed Israel Conference

    • Biotechnology innovator BiondVax Pharmaceuticals is dedicated to developing nanosized antibody (NanoAb) treatment
    • BiondVax is also leveraging its team experience in preclinical stage to Phase 3 clinical trial product development to generate new revenues by offering cGMP contract development and manufacturing organization (“CDMO”) services
    • The company recently exhibited its CDMO expertise as well as its NanoAb development pipeline at the 21st annual Biomed Israel conference, which drew over 6,000 attendees from a wide variety of international life sciences disciplines
    • BiondVax’s NanoAb drug candidate pipeline has expanded focus on immune system cytokine targets for treating psoriasis and psoriatic arthritis

    Israel-based biotechnology company BiondVax Pharmaceuticals (NASDAQ: BVXV) is building on positive preclinical data regarding its innovative inhaled anti-SARS-CoV-2 nanosized antibody (NanoAb) product with plans to develop further NanoAbs targeting immune system cytokines while the company expands its frontiers by beginning to offer contract development and manufacturing organization (“CDMO”) services.

    BiondVax showcased its CDMO services and expertise at the premier conference for international Life Science and HealthTech industries earlier this month in Israel. The 21st annual Biomed Israel drew more than 6,000 industry leaders, scientists, engineers, physicians, and investors from over 45 countries, providing BiondVax a worldwide stage for exhibiting its potential blockbuster products and state-of-the-art assets and services.

    “Senior executives and delegations from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to ‘shop for’ innovation in the field, in search of creative solutions, products and technologies, and the next big thing,” Biomed Israel Co-chairwoman Ruti Alon stated in a news release about the event (

    BiondVax has gained significant expertise in developing and producing current good manufacturing practice (“cGMP”) compliant drug candidates, working from preclinical stage to Phase 3 clinical trials. Making its cGMP manufacturing facility available for the development of other companies’ products helps to advance the potential of improving medical therapies and responding to unmet medical needs.

    The company’s CDMO services include aseptic filling, upstream and downstream process development, as well as analytical model development. BiondVax is contracting its suite of boutique end-to-end services ( to large pharmaceutical and biotech companies, alternative protein food tech companies, and smaller development-stage companies in general.

    Offering CDMO services “allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” CEO Amir Reichman stated in a year-end letter to shareholders (

    “The team already knows how to work together. The team has experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — everything works; it’s an oiled machine. Also the capacity and the capabilities are there,” Reichman said in a March interview with Digital Niche Agency that addressed BiondVax’s efforts to strengthen its value for its shareholders (

    A recent statement on the company’s quarterly financial results noted that the company has begun R&D activities for the innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis, both large market disorders with large unmet medical needs.

    For more information, visit the company’s website at

    NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

    About BioMedWire

    BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

    To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

    For more information, please visit

    Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

    BioMedWire (BMW)
    San Francisco, California
    415.949.5050 Office

    BioMedWire is part of the InvestorBrandNetwork.


    Select A Month

    Official NewsWire Relationships

    BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

    BioMedWire Currently Accepts



    Bitcoin Cash

    Bitcoin Cash





    USD Coin

    USD Coin

    Contact us: 415.949.5050